OptiNose (NASDAQ:OPTN) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of OptiNose (NASDAQ:OPTN) in a research note released on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock, down from their previous price objective of $18.00.

Separately, Lake Street Capital downgraded OptiNose from a “buy” rating to a “hold” rating and cut their price target for the stock from $17.00 to $9.00 in a research note on Thursday.

OptiNose Stock Performance

Shares of OPTN stock opened at $9.15 on Friday. OptiNose has a 1-year low of $4.82 and a 1-year high of $25.20. The company has a market capitalization of $92.05 million, a price-to-earnings ratio of -2.18 and a beta of -0.30. The stock’s fifty day simple moving average is $5.96 and its 200-day simple moving average is $8.17.

Insider Activity

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at $671,464.99. This represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 8,213 shares of company stock worth $43,643. 2.30% of the stock is owned by corporate insiders.

Institutional Trading of OptiNose

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of OptiNose in the 3rd quarter valued at approximately $61,000. State Street Corp grew its holdings in OptiNose by 14.2% during the third quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after purchasing an additional 42,500 shares during the last quarter. Geode Capital Management LLC raised its position in shares of OptiNose by 33.7% in the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock valued at $870,000 after purchasing an additional 326,918 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of OptiNose by 5.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock worth $2,061,000 after buying an additional 155,329 shares during the last quarter. Finally, Acorn Capital Advisors LLC bought a new stake in shares of OptiNose during the 4th quarter worth $2,824,000. Institutional investors and hedge funds own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.